ArticleFrontiers in oncology2023

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC.

Hongxiang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.